Company news
Halberd Corp. (OTC:HALB) news
Halberd Corp. news releases on 6ix. Latest, Dec 1, 2022: CORRECTION: Halberd Team Produces Peer Reviewed Article on Antibody Against Covid-19 Omicron Variant
Press releases — page 2
CORRECTION: Halberd Team Produces Peer Reviewed Article on Antibody Against Covid-19 Omicron Variant
November 30, 2022
Halberd Team Produces Peer Reviewed Article on Antibody Against Covid-19 Omicron Variant
November 29, 2022
Halberd Corporation Achieves Groundbreaking Pre-Clinical Endpoint by Eradicating Cancer Disease Antigen Linked to Breast Cancer
November 16, 2022
Halberd Signs Development and Marketing Agreement for Medications & Nutraceuticals
November 13, 2022
Hartman, CEO, and Dr. Felder, CTO of Halberd Corp Featured on The Street Reports Podcast
October 26, 2022
Halberd Laser Therapy Eliminates Over 90% of Multiple Antibiotic Resistant Bacteria in Minutes
October 17, 2022
Halberd Laser Therapy Eliminates over 90% of Multiple Antibiotic Resistant Bacteria in Minutes
October 17, 2022
Halberd Progresses from Eliminating Top Brain Disease Antigens from CSF To Eradication of Interleukin-6 From Human Blood Serum
October 11, 2022
Halberd Enters Strategic Alliance for Longevity, Alzheimer's Disease, and Cancer Early Detection, Prevention and Treatment
September 26, 2022
Halberd Demonstrates Precise Control of Key Cancer Related T-Cell Protein
August 22, 2022
NFL Retired Players Association Endorses Halberd Brain Injury Treatment Technology
August 3, 2022
Halberd Corp. Launches "Halberd Cancer Therapeutics, LTD" Wholly Owned Subsidiary
July 19, 2022
Halberd's Antibody Effective Against All 4 SARS-CoV-2 Mutations, Including Omicron
July 13, 2022
Halberd's Antibody Effective Against all 4 SARS-CoV-2 Mutations, Including Omicron
July 13, 2022
Halberd Corporation Update, CEO Letter and 2022 Expectations
July 11, 2022
Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer
June 20, 2022
Halberd Corp. and Mississippi State University Discuss Animal Testing as Prelude to FDA Certification
June 7, 2022
Halberd Corp. & Mississippi State University Discuss Animal Testing as Prelude to FDA Certification
June 7, 2022
Halberd Successfully Eliminates Excess Levels of Inflammatory Cytokines
May 23, 2022
Halberd Engages Professional Firm to Proceed with FDA Filings
May 17, 2022
Halberd Submits Audited Financials; Files Form-10 as First Step to Up-List to OTCQB
May 11, 2022
Halberd Submits Audited Financials; Files Form-10 as First Step to Up-list to OTCQB
May 11, 2022
Dr. Gregg Sturrus' TEDx Talk(R) Features Halberd's Extracorporeal Treatment of Neurodegenerative Diseases
April 28, 2022
Halberd CEO Letter
April 24, 2022
Halberd Eliminates E. Coli in 20 Minutes Vs. 7-10 Days with Conventional Antibiotics
April 17, 2022
Halberd Eliminates E. Coli in 20 Minutes vs. 7-10 Days with Conventional Antibiotics
April 17, 2022
Halberd Entering the Medical Metaverse
April 10, 2022
Halberd Entering the Medical Metaverse(TM)
April 10, 2022
Halberd Continues In-Vitro Successes With Elimination of Protein Linked to Depression
April 3, 2022
Infectious Disease Specialist Will Guide Halberd's Extracorporeal Elimination of Disease Antigens in Animals and Then Humans
March 15, 2022
Halberd Expands Its Technical Expertise with the Addition of Microbiology Professor
March 7, 2022
Halberd Expands Its Technical Expertise With the Addition of Microbiology Professor
March 7, 2022
Halberd's COVID-19 Antibody is the Only One In Competitive Tests to Bind to Omicron Variant
February 28, 2022
Halberd Medical Breakthrough for the Treatment of Neurodegenerative Diseases Affecting 36 Million Americans Annually
February 21, 2022
Halberd Eliminates 100% of Tau Protein From CSF - The 9th of 10 Target Neurodegenerative Disease Antigens
February 7, 2022
Halberd Achieves Landmark Selective Elimination of Tau From an Antigen Mixture
January 31, 2022
Halberd CEO Letter: 2021 Year-End & 2022 Outlook
January 24, 2022
Halberd CEO Letter: 2021 Year-End & 2022 Outlook
January 24, 2022
Halberd, Corp. (HALB) Reports Elimination of Target Antigens, Progressing to Treatments for Neurodegenerative Diseases
January 12, 2022
Halberd, Inc. (HALB) Reports Elimination of Target Antigens, Progressing to Treatments for Neurodegenerative Diseases
January 12, 2022
Halberd Corporation Now an Official US Government Contractor
January 4, 2022
Halberd Moves Closer to Proving Its Patented Technologies Eliminate Contributors to Neurodegenerative Diseases
December 20, 2021
Halberd Eradicates Another Inflammatory Cytokine, Interleukin-12, In Its Continuing Effort To Eliminate Neurodegenerative Diseases
December 14, 2021
Halberd Successfully Eradicates Interleukin-1 in Its Continued Progress Toward Eliminating Neurodegenerative Diseases
December 12, 2021
Halberd Successfully Eradicates Interluekin-1 in Its Continued Progress Toward Eliminating Neurodegenerative Diseases
December 12, 2021
Halberd Follow-Up Verification Tests Prove 100% Eradication of TNF-alpha, a Major Contributing Factor to Alzheimer's Disease and PTSD/CTE
December 5, 2021
Halberd Follow-up Verification Tests Prove 100% Eradication of TNF-alpha, a Major Contributing Factor to Alzheimer's Disease and PTSD/CTE
December 5, 2021
Halberd Successfully Eradicates TNF-alpha, Major Contributing Factor to Alzheimer's Disease
November 21, 2021
Halberd Successfully Eradicates TNF-a, a Major Contributing Factor to Alzheimer’s Disease
November 21, 2021
Halberd Files Additional Extracorporeal Patent Application: Treatment of Covid-19 By Exposure to Tuned Radio Frequency Waves
November 7, 2021